Physician profile
Rajee Paul
NPI 1336133156
$1,810.53
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $28.82 · 2021: $207 · 2022: $489 · 2023: $442 · 2024: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $300.27 | 2021-2024 | Farxiga, Breztri |
| Abbvie INC. | $239.71 | 2022-2023 | |
| Merz North America, INC. | $194.61 | 2019 | |
| Novo Nordisk INC | $158.61 | 2021 | |
| Amgen INC. | $143.07 | 2024 | Tepezza, Repatha, Otezla |
| Pharming Healthcare, INC. | $123.19 | 2023 | Ruconest |
| Janssen Pharmaceuticals, INC | $113.75 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $100.92 | 2024 | Eylea Hd |
| Mallinckrodt Hospital Products INC. | $96.78 | 2022 | |
| Allergan, INC. | $79.71 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $77.24 | 2019-2020 | |
| Alcon Vision LLC | $48.76 | 2019-2023 | Clareon |
| Alimera Sciences, INC. | $45.94 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.07 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.96 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.06 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajee Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.